You have free access to this content

Cancer

Cover image for Vol. 117 Issue 1

1 January 2011

Volume 117, Issue 1

Pages 1–230

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Incorporating fertility preservation into the care of young oncology patients (pages 1–10)

      Amanda J. Redig, Robert Brannigan, Steven J. Stryker, Teresa K. Woodruff and Jacqueline S. Jeruss

      Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25398

      • original image

      This commentary provides an overview of the range of fertility preservation options currently available and under development, using case-based discussions to illustrate ways in which fertility preservation can be incorporated into oncology care. Current guidelines in oncology and reproductive medicine are also reviewed to underscore the importance of communicating fertility preservation options to young patients with cancer.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Zoledronic acid use in cancer patients : More than just supportive care? (pages 11–23)

      Robert Coleman, Richard Cook, Vera Hirsh, Pierre Major and Allan Lipton

      Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25529

      • original image
      • original image
      • original image
      • original image

      Zoledronic acid reduced the risk of skeletal-related events in patients with bone lesions from advanced cancer and protected bone health in cancer patients who were receiving adjuvant endocrine therapy. Anticancer effects associated with zoledronic acid may contribute to the prolonged disease-free and recurrence-free survival observed in recent clinical studies in patients receiving adjuvant endocrine therapy.

    2. You have free access to this content
      Treatment recommendations for primary extradural meningiomas (pages 24–38)

      Austin Mattox, Betsy Hughes, James Oleson, David Reardon, Roger McLendon and Cory Adamson

      Version of Record online: 7 SEP 2010 | DOI: 10.1002/cncr.25384

      • original image
      • original image
      • original image
      • original image
      • original image

      This article describes the key features of primary extradural meningioma tumors to aid in diagnosis, presents the largest published review of all reported PEMs, and provides crucial treatment guidelines to surgeons unfamiliar with these challenging tumors.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (pages 39–47)

      Henry M. Kuerer, Aman U. Buzdar, Elizabeth A. Mittendorf, Francisco J. Esteva, Anthony Lucci, Luis M. Vence, Laszlo Radvanyi, Funda Meric-Bernstam, Kelly K. Hunt and William Fraser Symmans

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25399

      • original image
      • original image
      • original image

      Single-dose preoperative monotherapy with trastuzumab for patients with HER2-positive DCIS results in the early ability to mount antibody dependent cellular cytotoxicity mediated through natural killer cells and may also induce T-cell dependent humoral immunity.

    2. You have free access to this content
      Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 (pages 48–53)

      Semir Vranic, Bryan Teruya, Susan Repertinger, Pamela Ulmer, Jill Hagenkord and Zoran Gatalica

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25580

      • original image
      • original image
      • original image

      Increased CEP17 signals detected in invasive breast carcinomas may lead to discordant interpretation of gene amplification in a significant proportion of cases, depending on which criterion (ratio vs absolute number) is used for interpretation. However, increased gene dosage (>6 HER2 genes or HER2/CEP17 ratio >2.2), regardless of the evaluation method, is positively correlated with HER2 protein expression.

    3. You have free access to this content
      Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ (pages 54–62)

      Elaine S. Wai, Mary L. Lesperance, Cheryl S. Alexander, Pauline T. Truong, Matthew Culp, Patricia Moccia, Jennifer F. Lindquist and Ivo A. Olivotto

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25344

      • original image
      • original image

      Radiotherapy significantly decreased risk of local recurrence after breast-conserving surgery in patients with ductal carcinoma in situ. Additional boost radiotherapy and hypofractionation schedules did not significantly alter the effect of the radiotherapy.

    4. Gastrointestinal Disease
      You have free access to this content
      Endoscopic esophageal tumor length : A prognostic factor for patients with esophageal cancer (pages 63–69)

      Puja Gaur, Boris Sepesi, Wayne L. Hofstetter, Arlene M. Correa, Manoop S. Bhutani, Thomas J. Watson, Stephen G. Swisher and Members of the M. D. Anderson Esophageal Cancer Group and the University of Rochester School of Medicine and Dentistry Foregut Group

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25373

      • original image
      • original image
      • original image

      In this study, endoscopically measured tumor length was identified as an independent predictor of survival for patients with esophageal adenocarcinoma. The results indicated that this measure may be used to identify high-risk patients who may benefit from neoadjuvant therapy before they undergo surgical resection.

    5. You have free access to this content
      Expanding colorectal cancer screening among minority women (pages 70–76)

      Moshe Shike, Mark Schattner, Alvaro Genao, Winsome Grant, Margaret Burke, Ann Zauber, Lianne Russo and Valerie Cuyjet

      Version of Record online: 25 OCT 2010 | DOI: 10.1002/cncr.25566

      • original image

      Offering colorectal cancer screening to poor minority women at the time of mammography is an effective way to expand screening in this otherwise underserved population. Screening colonoscopy findings in this population were similar to those in the general population. Alternatives to traditional medical insurance are needed for the uninsured.

    6. You have free access to this content
      Phase 1 clinical trials in 83 patients with pancreatic cancer : The M. D. Anderson Cancer Center experience (pages 77–85)

      Christos Vaklavas, Apostolia-Maria Tsimberidou, Sijin Wen, David Hong, Jennifer Wheler, Chaan S. Ng, Aung Naing, Cynthia Uehara, Robert A. Wolff and Razelle Kurzrock

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25346

      • original image
      • original image
      • original image

      Of 83 patients with pancreatic cancer treated in the phase 1 program, the median survival duration from presentation in the phase 1 clinic was 5.0 months (95% confidence interval, 3.3-6.2), which compared favorably to the survival duration observed with best supportive care (3 months). The results suggest that phase 1 clinical trials offer a reasonable therapeutic approach for patients with advanced pancreatic cancer.

    7. You have free access to this content
      Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene (pages 86–95)

      Jianjun Zhang, Haiyan Guo, He Zhang, Haibo Wang, Guanxiang Qian, Xianqun Fan, Andrew R. Hoffman, Ji-Fan Hu and Shengfang Ge

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25522

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors identified FLI1, a gene involved in t(11;22)(q24:q12) reciprocal chromosomal translocation in Ewing sarcoma, as a novel target of miR-145, suggesting that miR-145 functions as a tumor suppressor by down-regulating oncogenic FLI1 in colon cancer.

    8. Genitourinary Disease
      You have free access to this content
      Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer (pages 96–102)

      Clair Beard, William B. Stason, Qian Wang, Judith Manola, Elizabeth Dean-Clower, Jeffery A. Dusek, Susan DeCristofaro, Ann Webster, Anne M. Doherty-Gilman, David S. Rosenthal and Herbert Benson

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25291

      • original image
      • original image

      This pilot randomized controlled trial (RCT) examined the clinical effects of 2 complementary (CAM) therapies—relaxation response therapy (RRT) and Reiki therapy—in men being treated with external beam radiotherapy (EBRx) for prostate cancer and documented the feasibility of conducting a RCT of CAM therapies in men undergoing EBRx for prostate cancer. It was found that RRT improved emotional well being and anxiety in study participants.

    9. You have free access to this content
      A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer (pages 103–109)

      Giovanni Lughezzani, Maxine Sun, Shahrokh F. Shariat, Lars Budäus, Rodolphe Thuret, Claudio Jeldres, Daniel Liberman, Francesco Montorsi, Paul Perrotte and Pierre I. Karakiewicz

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25345

      • original image

      A valuable graphical aid was developed for prediction of cancer-specific and other-cause mortality according to disease stage and patient age. It can help clinicians better stratify the risk-benefit ratio of radical cystectomy.

    10. Hematologic Malignancies
      You have free access to this content
      Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy (pages 110–115)

      Farshid Dayyani, Hagop Kantarjian, Susan O'Brien, Sherry Pierce, Dan Jones, Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes and Farhad Ravandi

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25585

      • original image

      To the best of the authors' knowledge, outcomes of patients with therapy-related acute promyelocytic leukemia (t-APL) who were treated with arsenic trioxide (ATO) as frontline regimens are not known. In the current study, survival rates for patients with t-APL who were treated with all-trans-retinoic acid (ATRA) plus ATO were compared with those for patients who received a chemotherapy-based induction regimen and found to be similar.

    11. You have free access to this content
      Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia (pages 116–124)

      William G. Wierda, Thomas J. Kipps, Michael J. Keating, Jennifer R. Brown, John G. Gribben, Mary Browning, Laura Z. Rassenti, Andrew W. Greaves, Donna Neuberg, Susan M. O'Brien and and the CLL Research Consortium

      Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25379

      • original image
      • original image
      • original image

      The results from this study demonstrated that self-administered, subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in alemtuzumab consolidation trials.

    12. Hepatobiliary Disease
      You have free access to this content
      Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma : Results of a phase 2 study (pages 125–133)

      Giuseppe Lombardi, Fable Zustovich, Fabio Farinati, Umberto Cillo, Alessandro Vitale, Giacomo Zanus, Martin Donach, Miriam Farina, Stefania Zovato and Davide Pastorelli

      Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25578

      • original image
      • original image

      The authors tested the combination of gemcitabine plus pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. This combination was demonstrated to be active and safe.

    13. Lung Disease
      You have free access to this content
      Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area (pages 134–142)

      Jeffrey W. Allen, Aamer Farooq, Thomas F. O'Brien and Raymond U. Osarogiagbon

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25334

      • original image
      • original image
      • original image
      • original image
      • original image

      The degree of compliance with quality measures as outlined by national leadership groups in surgical resection of non-small cell lung cancer patients is poor. We evaluated a consecutive series of NSCLC resections in a large metropolitan US city and compared the surgical procedures to three national guidelines. Interventions aimed at increasing the degree of lymph node sampling are needed.

    14. You have free access to this content
      Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors (pages 143–151)

      Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park and Myung-Ju Ahn

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25560

      • original image
      • original image

      Patients with wild-type epidermal growth factor receptor (WT EGFR)-positive nonsmall cell lung cancer (NSCLC) may benefit clinically from treatment with EGFR tyrosine kinase inhibitors (TKIs) through the regulation of amphiregulin expression. The results suggested that amphiregulin expression may be another potential marker for the selection of EGFR-TKI treatment in patients with WT EGFR-positive NSCLC.

    15. Melanoma
      You have free access to this content
      The expanding melanoma burden in California hispanics : Importance of socioeconomic distribution, histologic subtype, and anatomic location (pages 152–161)

      Ricardo A. Pollitt, Christina A. Clarke, Susan M. Swetter, David H. Peng, John Zadnick and Myles Cockburn

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25355

      The socioeconomic distribution of melanoma incidence and tumor thickness differed starkly between Hispanic and non-Hispanic white Californians, particularly among men. Melanoma prevention efforts targeted to Hispanics of lower socioeconomic status and increased physician awareness of melanoma patterns among Hispanics are needed.

    16. Neuro-Oncology
      You have free access to this content
      Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis (pages 162–174)

      Roberto Pallini, Lucia Ricci-Vitiani, Nicola Montano, Cristiana Mollinari, Mauro Biffoni, Tonia Cenci, Francesco Pierconti, Maurizio Martini, Ruggero De Maria and Luigi Maria Larocca

      Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25581

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In glioblastoma that recurred after radiochemotherapy, the fraction of CD133-positive cells increased by 4.6-fold compared with paired tumors at first diagnosis; however, increased CD133 expression was associated significantly with longer survival. By using chromosomal analysis and in vivo xenografts, the authors of this report demonstrated that the CD133-positive cell compartment of recurrent glioblastoma is composed of cancer stem cells and nontumor neural stem cells and that the relative amount of the latter cells favorably affects patient survival.

    17. Sarcoma
      You have free access to this content
      Clinical outcomes for patients with soft tissue sarcoma of the hand (pages 175–179)

      Mark E. Puhaindran, Rachel S. Rohde, Joanne Chou, Carol D. Morris and Edward A. Athanasian

      Version of Record online: 31 AUG 2010 | DOI: 10.1002/cncr.25593

      • original image

      This study assessed clinical outcomes for patients with soft tissue sarcoma of the hand. The results suggested that aggressive surgical treatment can result in better clinical outcomes, and underscored that care must be taken when planning biopsies of hand tumors.

    18. Discipline

      Disparities Research
      You have free access to this content
      The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care (pages 180–189)

      Rachel A. Freedman, Katherine S. Virgo, Yulei He, Alexandre L. Pavluck, Eric P. Winer, Elizabeth M. Ward and Nancy L. Keating

      Version of Record online: 11 OCT 2010 | DOI: 10.1002/cncr.25542

      • original image

      The authors observed that black women had modestly lower rates of guideline-recommended breast cancer care compared with white women. The lower rates in receipt of care were insensitive to adjustment for insurance and area-level socioeconomic status.

    19. Outcomes Research
      You have free access to this content
      Cognitive impairment in men with testicular cancer prior to adjuvant therapy (pages 190–196)

      Jeffrey S. Wefel, Damon J. Vidrine, Tracy L. Veramonti, Christina A. Meyers, Salma K. Marani, Harald J. Hoekstra, Josette E. H. M. Hoekstra-Weebers, Lokesh Shahani and Ellen R. Gritz

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25298

      A significant number of men with NSGCT exhibited cognitive impairment before chemotherapy. The domains of cognitive function most frequently affected include verbal learning, executive function, and fine motor dexterity.

    20. Pediatric Oncology
      You have free access to this content
      Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma (pages 197–206)

      Daniel Ka Leung Cheuk, Catherine A. Billups, Michael G. Martin, Cynthia R. Roland, Raul C. Ribeiro, Matthew J. Krasin and Carlos Rodriguez-Galindo

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25376

      • original image
      • original image

      The authors evaluated the long-term outcomes of childhood nasopharyngeal carcinoma. Although survival rates improved over the past 4 decades with cisplatin-based chemotherapy and higher radiotherapy doses, many survivors had long-term treatment-related morbidities.

    21. You have free access to this content
      Elevated expression of CXC chemokines in pediatric osteosarcoma patients (pages 207–217)

      Yiting Li, Ricardo Flores, Alexander Yu, M. Fatih Okcu, Jeffrey Murray, Murali Chintagumpala, John Hicks, Ching C. Lau and Tsz-Kwong Man

      Version of Record online: 30 AUG 2010 | DOI: 10.1002/cncr.25563

      • original image
      • original image
      • original image
      • original image

      Two CXC chemokines, CXCL4 and CXCL6, were higher in the plasma of osteosarcoma patients and frequently expressed in the tumor. Results showed that these 2 chemokines could be useful for prognostication of osteosarcoma, and targeting these chemokines and their receptors may also provide therapeutic potential.

    22. Psychosocial Oncology
      You have free access to this content
      Screening for major depression in cancer outpatients : The diagnostic accuracy of the 9-item patient health questionnaire (pages 218–227)

      Parvez Thekkumpurath, Jane Walker, Isabella Butcher, Laura Hodges, Annet Kleiboer, Mark O'Connor, Lucy Wall, Gordon Murray, Kurt Kroenke and Michael Sharpe

      Version of Record online: 24 AUG 2010 | DOI: 10.1002/cncr.25514

      • original image
      • original image
      • original image

      When the 9-item Patient Health Questionnaire (PHQ-9) was scored as a continuous measure with a cutoff score ≥8, it performed well in identifying major depressive disorder among cancer patients. The current findings indicated that the PHQ-9 should be considered as a screening instrument in this population.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
  6. Errata

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Erratum: Nervous System Post-Transplantation Lymphoproliferative Disorder (page 230)

      Daan Dierickx, Thomas Tousseyn and Gregor Verhoef

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25611

      This article corrects:

      Primary central nervous system post-transplantation lymphoproliferative disorder1

      Vol. 116, Issue 14, 3521, Version of Record online: 27 APR 2010

    2. You have free access to this content
      Erratum: Activity and Tolerability of Nilotinib: A Retrospective Multicenter Analysis of Chronic Myeloid Leukemia Patients Who Are Imatinib Resistant or Intolerant (page 230)

      Maya Koren-Michowitz, Philipp le Coutre, Justus Duyster, Christof Scheid, Panayiotis Panayiotidis, Witold Prejzner, Jacob M. Rowe, Michaela Schwarz, Neta Goldschmidt and Arnon Nagler

      Version of Record online: 27 AUG 2010 | DOI: 10.1002/cncr.25569

      This article corrects:

      Activity and tolerability of nilotinib

      Vol. 116, Issue 19, 4564–4572, Version of Record online: 19 AUG 2010

SEARCH

SEARCH BY CITATION